The Challenges, Solutions, and Strategies Driving Pharmaceutical Supply Chain Innovation

In recent years, pharmaceutical and biotechnology companies have come to understand that supply chains ultimately impact the delivery of healthcare, and supply chains can and should serve as value centers for their company and the end-user. While there has always been a focus on the supply chain in relation to on-time delivery, there has traditionally been less focus on strategic inventory management and supply chain optimization. However, the importance of intelligent supply chain management has become a focus as pharma companies have been challenged with shifting regulatory compliance, emerging markets, item-level serialization, product diversification, and learning to use data to control costs and drive value.

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

OTHER WHITEPAPERS
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Investing in Next-Generation Tokenization and Real-World Data to Unlock a More Precise and Complete Patient Journey

whitePaper | November 18, 2022

To realize the full potential of RWD, we must put the patient at the center and truly understand each patient’s unique circumstances over time. It’s certainly a tall order when the data we need is scattered across siloed systems and guarded by applicable and necessary patient privacy regulations.

Read More
news image

Shining a Light on Lipid Nanoparticle Characterization

whitePaper | October 3, 2022

Next-Generation Synthetic Biology Workflow Platform Codex DNA’s BioXp 9600 system is a next-generation high throughput platform intended for automated synthesis of gene fragments and clones from digital sequences.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

Starting Materials For Homeopathic Drug Products

whitePaper | December 31, 2021

The scope of this white paper includes GMPs relevant for mass manufacturing/batch53 processing of products intended for widescale retail marketing. Starting materials and 54 packaging components for drug products

Read More

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

Events